<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322657</url>
  </required_header>
  <id_info>
    <org_study_id>17-764</org_study_id>
    <nct_id>NCT03322657</nct_id>
  </id_info>
  <brief_title>Sugammadex Versus Neostigmine</brief_title>
  <official_title>Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether the use of Sugammadex for reversing the
      neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed
      recovery of neuromuscular function. Half of participates will receive Neostigmine with
      glycopyrrolate, while the other half will receive Sugammadex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Incomplete recovery from neuromuscular blocking agents (NMBAs) residual block after
      anesthesia and surgery continues to be a common problem in the postanesthesia care (PACU).

      Neostigmine remains the most common acetylcholinesterase inhibitor in the United States.
      However, administration of the drug significantly impairs genioglossus muscle activity when
      administered after full recovery from neuromuscular block. Moreover, doses of neostigmine
      exceeding 0.06 mg/kg increase the risk of respiratory complications independent of NMBAs
      effects.

      Sugammadex is a modified γ-cyclodextrin that rapidly reverses that effect of the steroidal
      nondepolarizing NMBAs rocuronium and vecuronium. Sugammadex forms a stable, inactive 1:1
      complex with rocuronium or vecuronium, reducing the amount of free NMBA available to bind to
      nicotinic acetylcholine receptors at the neuromuscular junction. Unlike neostigmine,
      sugammadex completely reverses even dense neuromuscular blocks.

      Patients having catheter-based neurointerventional procedures are kept deeply anesthetized.
      It is common to find patients nearly completely paralyzed at the end of neurointerventional
      procedures and have a markedly delayed emergence while waiting for muscle function to recover
      sufficiently to safely antagonize with neostigmine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in minutes to reach train of four (TOF) ratio ≥ 0.9 after the administration of reversal agent</measure>
    <time_frame>90 minutes after endotracheal extubation</time_frame>
    <description>The TOF ratio twitches ≥ 0.9 will be measured in continuous manner every 12 seconds from the administration of the reversal drug. The TOF ratio will be measured by acceleromyography of the force developed in the adductor pollicis muscle using the TOF scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time for extubation after administration of reversal agents</measure>
    <time_frame>Up to 4 hours after administration of reversal agents</time_frame>
    <description>Time from administration of reversal agent to tracheal extubation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Neostigmine with glycopyrrolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 4 mg/kg at the end surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Neostigmine injection</description>
    <arm_group_label>Neostigmine with glycopyrrolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Glycopyrrolate injection</description>
    <arm_group_label>Neostigmine with glycopyrrolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex injection</description>
    <arm_group_label>Sugammadex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years;

          -  American Society of Anesthesiologists (ASA) physical status 1-3;

          -  Scheduled for catheter-based neurointerventional procedures including coiling and
             stent insertion;

          -  General anesthesia.

        Exclusion Criteria:

          -  Suspected difficult intubation;

          -  Neuromuscular disorder;

          -  Renal impairment creatinine ≥ 2 mg /dl;

          -  Hepatic dysfunction;

          -  History of malignant hyperthermia;

          -  Allergy to neuromuscular blocking drugs, Sugammadex, neostigmine or glycopyrrolate;

          -  Perioperative respiratory infections and/or pneumonia;

          -  Intubated or unresponsive;

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ehab Farag, MD</last_name>
      <phone>216-444-7550</phone>
      <email>farage@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Roberta J Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Ehab Farag</investigator_full_name>
    <investigator_title>Ehab Farag, M.D.</investigator_title>
  </responsible_party>
  <keyword>Sugammadex</keyword>
  <keyword>Neostigmine</keyword>
  <keyword>Reversal of neuromuscular block</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

